Monjuvi

News

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

Patients

A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.